Germany, France, Italy, and Spain have develop into the most recent nations to droop utilizing the vaccine, becoming a member of Eire, Denmark, Thailand, the Netherlands, Norway, Iceland, Congo, and Bulgaria.
The European Medicines Company (EMA) mentioned suspending use of the AstraZeneca vaccine is “a precaution taken within the mild of their nationwide scenario.” However the EMA in addition to the World Well being Group mentioned information doesn’t present the vaccine precipitated the clots and other people ought to maintain getting vaccinated with it as a result of the profit outweighs the danger.
“Many hundreds of individuals develop blood clots yearly within the EU for various causes. The variety of thromboembolic occasions general in vaccinated individuals appears to not be increased than that seen within the common inhabitants,” the EMA mentioned in an announcement.
AstraZeneca defended the security of the vaccine.
“Round 17 million individuals within the EU and UK have now obtained our vaccine, and the variety of circumstances of blood clots reported on this group is decrease than the a whole bunch of circumstances that will be anticipated among the many common inhabitants,” Ann Taylor, chief medical officer, mentioned in a information launch.
“The character of the pandemic has led to elevated consideration in particular person circumstances and we’re going past the usual practices for security monitoring of licensed medicines in reporting vaccine occasions, to make sure public security.”
AstraZeneca says scientific trials present its vaccine has an efficacy of about 70% in comparison with the 95% and 94% efficacy for the Pfizer and Moderna vaccines, respectively. All three are being utilized in Europe.
The World Well being Group licensed the AstraZeneca-College of Oxford vaccine on Feb. 15. That allowed the United Nations to distribute doses to low- and middle-income nations.
AstraZeneca says it plans to hunt emergency use authorization from the FDA quickly.